This has been the subject of many papers. It seems to depend on age, amount of liver damage, genotype, socio-economic group, drugs used, and length of Rx. Psychological and physical side effects account for most of the failures to complete Rx, together with those who have to finish Rx due to poor response. Pre-existing conditions, such as diabetes, mental problems etc. increase this number.
The highest rate is in cirrhotic, older patients with Geno 1 or 3. Since the introduction of the antiproteases, the number of Geno 1's who drop out, has increased markedly. My doc showed me a survey where 45% of Incivek patients failed to complete the course, compared to about 25% of the Victrelis patients. There has been wide variation in surveys, as you would expect, but the range of drop-outs is between 15 and 50%. With the new DAA's, one would hope this figure will drop dramatically.
Patient education, full pre-Rx evaluation, and the skill/experience of the Hepatologist all play a significant role.
rotting to the core said
Aug 30, 2013
Being as to how I am starting my 40th week of treatment, I can't help but be curious as to how many people have been able to succeed in completion of of treatment. What I have found suggests it is less than 25%. Of course that is an old study done by the VA many years ago. Does any one have more current information?
I have always heard many can't tolerate treatment for many reasons, I am so grateful for my support system, with which I could never have made it even this far.
Daa's= Direct Acting Antivirals. Cheers.
DAA's?
Hi Timothy,
This has been the subject of many papers. It seems to depend on age, amount of liver damage, genotype, socio-economic group, drugs used, and length of Rx. Psychological and physical side effects account for most of the failures to complete Rx, together with those who have to finish Rx due to poor response. Pre-existing conditions, such as diabetes, mental problems etc. increase this number.
The highest rate is in cirrhotic, older patients with Geno 1 or 3. Since the introduction of the antiproteases, the number of Geno 1's who drop out, has increased markedly. My doc showed me a survey where 45% of Incivek patients failed to complete the course, compared to about 25% of the Victrelis patients. There has been wide variation in surveys, as you would expect, but the range of drop-outs is between 15 and 50%. With the new DAA's, one would hope this figure will drop dramatically.
Patient education, full pre-Rx evaluation, and the skill/experience of the Hepatologist all play a significant role.
Being as to how I am starting my 40th week of treatment, I can't help but be curious as to how many people have been able to succeed in completion of of treatment. What I have found suggests it is less than 25%. Of course that is an old study done by the VA many years ago. Does any one have more current information?
I have always heard many can't tolerate treatment for many reasons, I am so grateful for my support system, with which I could never have made it even this far.
Tiomthy